Avicanna Inc Earnings Call Highlights Margin Turnaround

Avicanna Inc ((TSE:AVCN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Avicanna Inc’s latest earnings call struck a cautiously optimistic tone as management balanced steady but flat revenue with notable gains in profitability, cash efficiency, and scientific progress. Executives highlighted stronger margins, leaner operations, and advancing clinical and IP milestones, while acknowledging lingering commercialization hurdles, regulatory uncertainty, and pressure on the company’s share price.

Revenue Plateau but Profitability Metrics Advance

Avicanna reported 2025 revenue of $25.5 million, essentially unchanged from the prior year, underscoring a plateau in top-line growth. However, profitability improved as gross profit reached $13.5 million and gross margin climbed to 53%, up ten percentage points from 2024, indicating better pricing, mix, and cost control.

EBITDA and Net Loss Show Meaningful Progress

Adjusted EBITDA improved by 71% year over year, narrowing to a modest full-year loss of $300,000 and turning positive in the fourth quarter with $310,000. Net loss also moved in the right direction, shrinking 41% from $4.6 million in 2024 to $2.7 million in 2025, suggesting the company is edging closer to sustainable profitability.

Cost Discipline and Liquidity Strengthen the Balance Sheet

Operating expenses were reduced by $1.5 million, a 9% annual decline, demonstrating ongoing cost discipline across the business. Working capital improved by 23% in 2025, giving Avicanna a stronger liquidity buffer to support operations and selective growth initiatives without overreliance on fresh capital.

Low Leverage and Reduced Dependence on New Capital

The company emphasized its conservative balance sheet, highlighting the absence of structured debt as a key de-risking factor for investors. External financing was limited to a $1 million non-brokered private placement in 2025, down sharply from $4.8 million in 2024, pointing to a deliberate shift toward self-funded growth.

Broader Canadian Footprint and MyMedi Momentum

Domestically, Avicanna expanded its Canadian commercial footprint to roughly 50 SKUs and 170 listings, representing a 26% increase year over year. Sell-through of Avicanna-branded products on the MyMedi platform grew from 17.5% to 19.7% of MyMedi sales in Q4, a roughly 12% relative gain that signals strengthening brand traction.

International Expansion and Aureus Quality Upgrades

Internationally, the company entered its 24th market and grew exports into Europe and Australia, with its Santa Marta Golden joint venture contributing $1.9 million in revenue. In Colombia, the Aureus platform improved organic premium flower quality to better meet export demand, reinforcing Avicanna’s supply base for global markets.

Drug Delivery Platforms and Patent Portfolio Deepen

On the R&D front, Avicanna finalized two proprietary self-emulsifying delivery platforms, including the PwdRX format, which showed sharply higher bioavailability and peak concentrations versus MCT oil in vitro. The company filed a provisional patent for PwdRX and secured a new U.S. patent for a topical cannabinoid composition, further bolstering its IP moat.

Clinical Evidence Builds for Medical Cannabis Pipeline

Clinical evidence advanced with a national real-world evidence study of roughly 450 patients published in the Canadian Journal of Pain, showing significant improvements across multiple endpoints over 24 weeks. The pipeline progressed as Avicanna launched a Phase II randomized trial in osteoarthritic pain and obtained regulatory clearance for a Phase I dose-finding study.

Flat Top Line and Ongoing Losses Temper Enthusiasm

Despite margin gains, management acknowledged that overall revenue remained stuck at $25.5 million, reflecting modest or no top-line growth. Full-year profitability still eluded the company as adjusted EBITDA finished slightly negative and the net loss, though reduced, remained material at $2.7 million.

Share Overhang and Thin Trading Hurt the Stock

Leadership pointed to a major shareholder selling down its position and low liquidity on the TSX as drivers of ongoing equity price pressure. This combination has created an overhang on the share price, dampening market valuation even as operating metrics and scientific progress move in a positive direction.

International Segment Still Small Versus Canada

While management touted its presence in 24 markets, it conceded that international revenues, including the $1.9 million from Santa Marta Golden, remain small compared with Canadian sales. Expanding this segment will require navigating complex, country-specific regulatory frameworks that can slow scaling and add execution risk.

Early-Stage Launch for Trunerox in Colombia

The company’s first pharmaceutical product, Trunerox, received approval in Colombia and entered a soft commercial launch in early 2026. Management stressed that this is an early learning phase and that meaningful revenue contribution and proof of commercial scale will only become clear over time.

Regulatory and U.S. Market Path Still Uncertain

Avicanna’s U.S. ambitions hinge in part on potential changes to federal cannabis scheduling and on progress toward a senior-exchange listing. Both paths are subject to timing and regulatory uncertainty, and management framed them as important but non-guaranteed sources of future upside rather than near-term drivers.

Portfolio Streamlining and Asset-Light Execution Risks

Management is pruning underperforming SKUs and leaning on an outsourced, asset-light manufacturing model, which supports capital efficiency. However, this strategy underscores ongoing product-market-fit adjustments and brings potential supply chain and quality-control risks that could impact consistency if not tightly managed.

Constrained Capital May Limit Rapid Scaling

By raising only $1 million in 2025, Avicanna highlighted its reduced dependence on external funding and improved internal cash generation. At the same time, the limited capital inflow could cap the pace of expansion if operating cash flow falls short, potentially slowing the ramp of promising international and pharmaceutical initiatives.

Guidance and Outlook for 2026

For 2026, management guided toward continued profitable, capital-light scaling, anchored by internationalizing the RHO Phyto line and rolling out a 3.0 generation of fast-acting products. The company aims to leverage its new fluid and PwdRX delivery platforms, scale Aureus exports, expand into new geographies including Australia, and advance clinical programs and a potential U.S. listing, all while building on improved margins and a strengthening balance sheet.

Avicanna’s earnings call painted a picture of a company tightening its operations and deepening its scientific foundation while wrestling with flat revenue and market headwinds. Investors will be watching whether margin gains, IP and clinical momentum, and international and pharmaceutical launches can translate into sustainable top-line growth and consistent profitability over the next few years.